ST Elevation Myocardial Infarction Clinical Trial
Official title:
Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction
Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction. Objective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI. Design: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design. Innovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.
Status | Recruiting |
Enrollment | 202 |
Est. completion date | March 31, 2025 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI) 3. CRP elevation of =7 mg/l measured between 6 to 16 hours after primary PCI 4. Eligible for primary PCI 5. Age =18 years 6. Written informed consent Exclusion Criteria: 1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI. 2. Persistent hemodynamic instability (Killip class >2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan. 3. The patient is febrile (temperature >38°C) or has experienced an acute infection with fever in the last 14 days. 4. CRP >15 mg/l at time of hospital admission. 5. Chronic inflammatory disease. 6. Known history of severe hepatic failure 7. Chronic kidney disease with a creatinine clearance <30ml/min./1.73m² 8. Contraindication to CMR. 9. Pre-STEMI life expectancy of <1 year 10. Participation in another interventional trial 11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad) 12. Pregnancy |
Country | Name | City | State |
---|---|---|---|
Austria | University Clinic for Cardiology and Nephrology, Medical University of Graz | Graz | |
Austria | University Clinic of Internal Medicine III, Cardiology and Angiology. University Clinic of Internal Medicine IV, Nephrology and Hypertensiology. University Clinic of Radiology. | Innsbruck | |
Austria | University Clinic of Internal Medicine II, Paracelsus Medical University Salzburg | Salzburg | |
Germany | Leipzig Heart Center | Leipzig | |
Germany | Medical Clinic II - University Heart Center Lübeck | Lübeck | Schleswig-Holstein |
Lead Sponsor | Collaborator |
---|---|
Medical University Innsbruck |
Austria, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary efficacy endpoint | Infarct size expressed as % of left ventricular myocardial mass (LVMM) as visualized by cardiac magnetic resonance (CMR) imaging at 5 ± 2 days post PCI | 5 ± 2 days post PCI | |
Secondary | Safety endpoint | Adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) during hospitalization for the index event | during hospitalization for the index event | |
Secondary | All-cause mortality or hospitalization for heart failure within 12 months after randomization | All-cause mortality or hospitalization for heart failure within 12 months after randomization (endpoint of interest with respect to the two-stage adaptive design) | within 12 months after randomization | |
Secondary | CMR endpoints defined as: Left ventricular ejection fraction and microvascular obstruction and exploratory (intramyocardial hemorrhage, edema extent, myocardial salvage, native T1 mapping, strain) | CMR endpoints will be assessed at baseline, 4 and 12 months CMR follow-up study and are defined according to the Journal of American College of Cardiology Scientific Expert Consensus document. | at baseline, 4 months and 12 months after PCI for STEMI | |
Secondary | Hospitalization for heart failure within 12 months after randomization | within 12 months after randomization | ||
Secondary | Cardiovascular mortality at 12 months | within 12 months after randomization | ||
Secondary | CRP concentrations | CRP concentrations during index hospitalization | during hospitalization for the index event | |
Secondary | Left ventricular thrombus formation | 5 ± 2 days, 4 months, 12 months post PCI | ||
Secondary | Biomarker concentrations of myocardial necrosis (enzymatic infarct size; high-sensitivity troponin T) | at baseline, 4 months, 12 months post PCI | ||
Secondary | Biomarker concentrations of hemodynamic stress (N-terminal pro-B-Type Natriuretic Peptide) | at baseline, 4 months, 12 months post PCI | ||
Secondary | Renal function (eGFR) | as measured by the MDRD and CKD-EPI formula | during hospitalization for the index event | |
Secondary | Renal function (Cystatin C-based calculation of creatinine clearance) | during hospitalization for the index event | ||
Secondary | Cardiac autonomic function: Deceleration capacity of heart rate | 5 ± 2 days, 4 months, 12 months post PCI | ||
Secondary | Cardiac autonomic function: Heart rate variability | 5 ± 2 days, 4 months, 12 months post PCI | ||
Secondary | Cardiac autonomic function: Periodic repolarization dynamics | 5 ± 2 days, 4 months, 12 months post PCI | ||
Secondary | Cardiac autonomic function: Baroreflex sensitivity | 5 ± 2 days, 4 months, 12 months post PCI | ||
Secondary | Cardiac autonomic function: Skin sympathetic nerve activity | 5 ± 2 days, 4 months, 12 months post PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05601999 -
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT06147986 -
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
|
Phase 2 | |
Not yet recruiting |
NCT05881382 -
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
|
Phase 3 | |
Enrolling by invitation |
NCT02615015 -
SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls
|
N/A | |
Recruiting |
NCT05812963 -
IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT05450757 -
Shanghai ST-segment Elevation Myocardial Infarction Cohort
|
||
Active, not recruiting |
NCT03278509 -
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
|
Phase 4 | |
Completed |
NCT03156699 -
The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
|
||
Not yet recruiting |
NCT03266328 -
Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University
|
N/A | |
Not yet recruiting |
NCT03263468 -
Revascularization StrategIes for ST Elevation Myocardial Infarction Trial
|
N/A | |
Enrolling by invitation |
NCT04970238 -
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
|
Phase 4 | |
Recruiting |
NCT02557217 -
NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
|
Phase 2 | |
Recruiting |
NCT02224534 -
Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT01136187 -
Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Not yet recruiting |
NCT04063345 -
Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03646357 -
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
|
Phase 4 | |
Completed |
NCT03740776 -
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
|
||
Completed |
NCT03984071 -
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
|